Global Rare Disease Genetic Testing Market Report 2022: Government & Regulatory Support for Rare Disease Diagnosis to Drive Growth
September 16, 2022 04:28 ET | Research and Markets
Dublin, Sept. 16, 2022 (GLOBE NEWSWIRE) -- The "Rare Disease Genetic Testing Market Size, Share & Trends Analysis Report by Disease Type (Neurological, CVDs), by Specialty (Molecular,...
Florida Cancer Specialists & Research Institute Celebrates Addition of Next-Generation Genomic Testing Capabilities to Advance Precision Oncology Approach to Patient Care
September 06, 2022 12:26 ET | Florida Cancer Specialists & Research Institute
Fort Myers, Fla., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Florida Cancer Specialists & Research Institute, LLC (FCS) celebrated the addition of genomic testing capabilities at its Next Generation...
Une nouvelle étude publiée dans le Clinical Cancer Research Journal met en avant l’utilisation du test EndoPredict pour éclairer les décisions thérapeutiques chez les patientes préménopausées atteintes d’un cancer du sein
August 31, 2022 08:00 ET | Myriad Genetics, Inc.
Le test EndoPredict de Myriad Genetics identifie avec précision les femmes préménopausées atteintes d'un cancer du sein RE+, HER2- qui pourraient éviter une chimiothérapie adjuvante sans perte de...
Neue Studie, im Clinical Cancer Research Journal veröffentlicht, unterstreicht die Bedeutung des EndoPredict-Tests zur Information über die Behandlung von prämenopausalen Brustkrebs-Patientinnen
August 31, 2022 08:00 ET | Myriad Genetics, Inc.
Myriad Genetics’ EndoPredict-Test identifiziert präzise prämenopausale Frauen mit ER+, HER2-Brustkrebs, die eine adjuvante Chemotherapie vermeiden können SALT LAKE CITY, Aug. 31, 2022 (GLOBE...
Un nuovo studio pubblicato sulla rivista Clinical Cancer Research mette in evidenza l’impiego del test EndoPredict per indicare quale trattamento adottare in pazienti con tumore al seno in premenopausa
August 31, 2022 08:00 ET | Myriad Genetics, Inc.
Il test EndoPredict di Myriad Genetics ha identificato in modo accurato le donne in premenopausa con carcinoma mammario ER+, HER2- che potevano con sicurezza evitare la chemioterapia adiuvante SALT...
Nuevo estudio publicado en Clinical Cancer Research Journal destaca el uso de la prueba EndoPredict para informar el tratamiento en pacientes premenopáusicas con cáncer de mama
August 31, 2022 08:00 ET | Myriad Genetics, Inc.
La prueba EndoPredict de Myriad Genetics identificó con precisión a mujeres premenopáusicas con cáncer de mama ER+, HER2- que podrían evitar la quimioterapia adyuvante de forma segura SALT LAKE CITY,...
Novo estudo publicado no Clinical Cancer Research Journal destaca o uso do teste EndoPredict para informar o tratamento em pacientes com câncer de mama na pré-menopausa
August 31, 2022 08:00 ET | Myriad Genetics, Inc.
O teste EndoPredict, da Myriad Genetics, identificou com precisão mulheres na pré-menopausa com câncer de mama ER+, HER2- que poderiam evitar, com segurança, a quimioterapia adjuvante SALT LAKE CITY,...
New Study Published in Clinical Cancer Research Journal Highlights Use of EndoPredict Test to Inform Treatment for Premenopausal Breast Cancer Patients
August 31, 2022 08:00 ET | Myriad Genetics, Inc.
Myriad Genetics’ EndoPredict test accurately identified premenopausal women with ER+, HER2- breast cancer who could safely avoid adjuvant chemotherapy SALT LAKE CITY, Aug. 31, 2022 (GLOBE NEWSWIRE)...
GENE logo.png
GENE Momentum building - a year in review
August 30, 2022 08:00 ET | Genetic Technologies Ltd
MELBOURNE, Australia, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in guideline driven genomics-based tests in health,...
22157.jpg
Gene Amplification Technologies Global Market Report 2022: Advances in Genome Sequencing to Spur Industry Growth
August 25, 2022 06:28 ET | Research and Markets
Dublin, Aug. 25, 2022 (GLOBE NEWSWIRE) -- The "Gene Amplification Technologies - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global Gene...